These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

851 related items for PubMed ID: 19158417

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Amyloid precursor protein cytoplasmic domain with phospho-Thr668 accumulates in Alzheimer's disease and its transgenic models: a role to mediate interaction of Abeta and tau.
    Shin RW, Ogino K, Shimabuku A, Taki T, Nakashima H, Ishihara T, Kitamoto T.
    Acta Neuropathol; 2007 Jun; 113(6):627-36. PubMed ID: 17431643
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome.
    Oddo S, Billings L, Kesslak JP, Cribbs DH, LaFerla FM.
    Neuron; 2004 Aug 05; 43(3):321-32. PubMed ID: 15294141
    [Abstract] [Full Text] [Related]

  • 6. [The lesions of Alzheimer's disease: which therapeutic perspectives?].
    Duyckaerts C, Perruchini C, Lebouvier T, Potier MC.
    Bull Acad Natl Med; 2008 Feb 05; 192(2):303-18; discussion 318-21. PubMed ID: 18819685
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Reduction of aggregated Tau in neuronal processes but not in the cell bodies after Abeta42 immunisation in Alzheimer's disease.
    Boche D, Donald J, Love S, Harris S, Neal JW, Holmes C, Nicoll JA.
    Acta Neuropathol; 2010 Jul 05; 120(1):13-20. PubMed ID: 20532897
    [Abstract] [Full Text] [Related]

  • 9. Different tau epitopes define Abeta42-mediated tau insolubility.
    Pennanen L, Götz J.
    Biochem Biophys Res Commun; 2005 Dec 02; 337(4):1097-101. PubMed ID: 16226718
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. [Treatment strategy of Alzheimer's disease: pause in clinical trials of Abeta vaccine and next steps].
    Kuzuhara S.
    Brain Nerve; 2010 Jul 02; 62(7):659-66. PubMed ID: 20675870
    [Abstract] [Full Text] [Related]

  • 12. The expression of calcium/calmodulin-dependent protein kinase II-alpha in the hippocampus of patients with Alzheimer's disease and its links with AD-related pathology.
    Wang YJ, Chen GH, Hu XY, Lu YP, Zhou JN, Liu RY.
    Brain Res; 2005 Jan 07; 1031(1):101-8. PubMed ID: 15621017
    [Abstract] [Full Text] [Related]

  • 13. Wnt signaling in Alzheimer's disease: up or down, that is the question.
    Boonen RA, van Tijn P, Zivkovic D.
    Ageing Res Rev; 2009 Apr 07; 8(2):71-82. PubMed ID: 19101658
    [Abstract] [Full Text] [Related]

  • 14. Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain.
    Tapiola T, Alafuzoff I, Herukka SK, Parkkinen L, Hartikainen P, Soininen H, Pirttilä T.
    Arch Neurol; 2009 Mar 07; 66(3):382-9. PubMed ID: 19273758
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Proteases and lipoprotein receptors in Alzheimer's disease.
    Makarova A, Williams SE, Strickland DK.
    Cell Biochem Biophys; 2004 Mar 07; 41(1):139-78. PubMed ID: 15371644
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Tau hyperphosphorylation correlates with reduced methylation of protein phosphatase 2A.
    Zhou XW, Gustafsson JA, Tanila H, Bjorkdahl C, Liu R, Winblad B, Pei JJ.
    Neurobiol Dis; 2008 Sep 07; 31(3):386-94. PubMed ID: 18586097
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 43.